- Home
- MDGL vs LFUS Comparison
MDGL vs LFUS Comparison
Compare MDGL & LFUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDGL
- LFUS
- Stock Information
- Founded
- MDGL 2011
- LFUS 1927
- Country
- MDGL United States
- LFUS United States
- Employees
- MDGL N/A
- LFUS N/A
- Industry
- MDGL Biotechnology: Pharmaceutical Preparations
- LFUS Electrical Products
- Sector
- MDGL Health Care
- LFUS Energy
- Exchange
- MDGL Nasdaq
- LFUS Nasdaq
- Market Cap
- MDGL 6.4B
- LFUS 5.9B
- IPO Year
- MDGL N/A
- LFUS N/A
- Fundamental
- Price
- MDGL $340.14
- LFUS $236.70
- Analyst Decision
- MDGL Buy
- LFUS Buy
- Analyst Count
- MDGL 14
- LFUS 5
- Target Price
- MDGL $351.67
- LFUS $278.75
- AVG Volume (30 Days)
- MDGL 392.5K
- LFUS 97.4K
- Earning Date
- MDGL 02-26-2025
- LFUS 01-28-2025
- Dividend Yield
- MDGL N/A
- LFUS 1.18%
- EPS Growth
- MDGL N/A
- LFUS N/A
- EPS
- MDGL N/A
- LFUS 7.78
- Revenue
- MDGL $76,813,000.00
- LFUS $2,195,070,000.00
- Revenue This Year
- MDGL N/A
- LFUS N/A
- Revenue Next Year
- MDGL $195.95
- LFUS $4.71
- P/E Ratio
- MDGL N/A
- LFUS $30.42
- Revenue Growth
- MDGL N/A
- LFUS N/A
- 52 Week Low
- MDGL $168.25
- LFUS $222.91
- 52 Week High
- MDGL $368.29
- LFUS $275.58
- Technical
- Relative Strength Index (RSI)
- MDGL 61.81
- LFUS 48.35
- Support Level
- MDGL $266.44
- LFUS $230.04
- Resistance Level
- MDGL $343.97
- LFUS $240.40
- Average True Range (ATR)
- MDGL 20.88
- LFUS 5.44
- MACD
- MDGL 2.00
- LFUS 0.55
- Stochastic Oscillator
- MDGL 92.59
- LFUS 55.24
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.
About LFUS Littelfuse Inc.
Littelfuse is a primary provider of circuit protection products (such as fuses and relays) into the transportation, industrial, telecommunications, and consumer electronics end markets. The firm is also increasing its power semiconductor business, where it predominantly serves industrial end markets and is breaking into electric vehicle charging infrastructure. Littelfuse has 17,000 global employees.